Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis

Clinica Chimica Acta

Volumn 404, Issue 2, 2009, Pages 119-123

  Hua, Yihong ^a   Song, Li ^a   Wu, Naqiong ^a   Xie, Gaoqiang ^a   Lu, Xiangfeng ^a   Fan, Xiaohan ^a   Meng, Xianmin ^a   Gu, Dongfeng ^a   Yang, Yuejin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

MMP 2; Polymorphism; Prognosis; Systolic heart failure

Indexed keywords

GELATINASE A;

ADULT; AGED; ALLELE; ARTICLE; CHINESE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART BUNDLE BRANCH BLOCK; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MMP 2 GENE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SYSTOLIC HEART FAILURE;

AGED; ALLELES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67349122033     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.03.030     Document Type: Article

References (42)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 112 (2005) 154-235
2. Anselmi A., Suarez J.A., Anselmi G., et al. Primary cardiomyopathy in identical twins. Am J Cardiol 35 (1975) 97-102
3. Littler W.A. Twin studies in hypertrophic cardiomyopathy. Br Heart J 34 (1972) 1147-1151
4. Indik J.H., Smith D.E., Sobonya R.E., et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a case report of identical twins with heart failure. Pacing Clin Electrophysiol 25 (2002) 1387-1390
5. Morita H., Seidman J., and Seidman C.E. Genetic causes of human heart failure. J Clin Invest 115 (2005) 518-526
6. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 (2008) 2544-2565
7. Spinale F.G. Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J 25 (2004) 631-633
8. Spinale F.G., Coker M.L., Thomas C.V., et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
9. Noji Y., Shimizu M., Ino H., et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 68 (2004) 355-360
10. Banfi C., Cavalca V., Veglia F., et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26 (2005) 481-488
11. Tziakas D.N., Chalikias G.K., Papaioakeim M., et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96 (2005) 1449-1451
12. George J., Patal S., Wexler D., et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150 (2005) 484-487
13. Lalu M.M., Pasini E., Schulze C.J., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26 (2005) 27-35
14. Wang W., Schulze C.J., Suarez-Pinzon W.L., et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106 (2002) 1543-1549
15. Wang G.Y., Bergman M.R., Nguyen A.P., et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69 (2006) 688-696
16. Conrad C.H., Brooks W.W., Hayes J.A., et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91 (1995) 161-170
17. Fatar M., Stroick M., Steffens M., et al. Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis 26 (2008) 113-119
18. Beránek M., Kolar P., Tschoplova S., et al. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 14 (Jun 14 2008) 1114-1121
19. Langers A.M., Sier C.F., Hawinkels L.J., et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 98 (2008) 1820-1823
20. Yu C., Zhou Y., Miao X., et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64 (Oct 15 2004) 7622-7628
21. Pannu H., Kim D.H., Guo D., et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 105 3 (Sep 2006) 418-423
22. Vasku A., Goldbergova M., Holla L.I., et al. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin Chem Lab Med 41 10 (Oct 2003) 1299-1303
23. Mizon-Gerard F., de Groote P., Lamblin N., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25 (2004) 688-693
24. Harendza S., Lovett D.H., Panzer U., et al. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 278 (2003) 20490-20499
25. Price S.J., Greaves D.R., and Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276 (Mar 9 2001) 7549-7558
26. Schaid D.J., Rowland C.M., Tines D.E., et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
27. Coker M.L., Doscher M.A., Thomas C.V., et al. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 277 (1999) H777-H787
28. Tyagi S.C., Kumar S., and Glover G. Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. J Cell Biochem 58 (1995) 360-371
29. Birkedal-Hansen H., Moore W.G., Bodden M.K., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 (1993) 197-250
30. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 (1999) 906-911
31. Fernandez-Patron C., Stewart K.G., Zhang Y., et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 (2000) 670-676
32. Martinez A., Oh H.R., Unsworth E.J., et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 (2004) 413-418
33. Conrad C.H., Brooks W.W., Hayes J.A., et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91 (1995) 161-170
34. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
35. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15 (2005) 490-495
36. Couillard J., Demers M., Lavoie G., and St-Pierre Y. The role of DNA hypomethylation in the control of stromelysin gene expression. Biochem Biophys Res Commun 342 (2006) 1233-1239
37. Sudarsanam P., and Winston F. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends Genet 16 (2000) 345-351
38. Overall C.M., Wrana J.L., and Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 266 (1991) 14064-14071
39. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
40. Chapman R.E., and Spinale F.G. Extra cellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol 286 (2004) H1-H10
41. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., McClure C.D., Spinale F.G., and Zile M.R. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
42. Langers A.M., Sier C.F., Hawinkels L.J., Kubben F.J., van Duijn W., van der Reijden J.J., Lamers C.B., Hommes D.W., and Verspaget H.W. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 98 (2008) 1820-1823